Breyanzi Disease Interactions
There are 2 disease interactions with Breyanzi (lisocabtagene maraleucel).
Lisocabtagene (applies to Breyanzi) infection
Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral
Lisocabtagene maraleucel should not be administered to patients with active infection or inflammatory disorders. Monitor patients for signs or symptoms of infection and treat appropriately.
Lisocabtagene maraleucel (applies to Breyanzi) hepatitis B reactivation
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Infectious Hepatitis
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells, such as lisocabtagene maraleucel. Screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing is advised. In patients with prior history of HBV, consider concurrent antiviral suppressive therapy to prevent HBV reactivation per standard guidelines.
Switch to professional interaction data
Breyanzi drug interactions
There are 294 drug interactions with Breyanzi (lisocabtagene maraleucel).
Report options
More about Breyanzi (lisocabtagene maraleucel)
- Breyanzi consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Latest FDA alerts (3)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Rituxan
Rituxan infusion is used to treat certain leukemias and lymphomas and some non-cancer conditions ...
Truxima
Truxima is used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid ...
Monjuvi
Monjuvi (tafasitamab-cxix) is used for the treatment of relapsed or refractory diffuse large B-cell ...
Kymriah
Kymriah is used to treat acute lymphoblastic leukemia (ALL) that is relapsing or refractory in ...
Yescarta
Yescarta is used to treat large B-cell lymphoma and follicular lymphoma, two types of non-Hodgkin ...
Polivy
Polivy (polatuzumab vedotin-piiq) is a targeted treatment that may be used to treat diffuse large ...
Xpovio
Xpovio is used to treat multiple myeloma (MM) or relapsed/refractory diffuse large B-cell lymphoma ...
Lunsumio
Lunsumio (mosunetuzumab-axgb) is used for the treatment of relapsed or refractory follicular ...
Columvi
Columvi is used to treat certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
